Dr. Stella M. Ling, MD, MPH

Dr. Ling practices at Southern Ohio Medical Center in Portsmouth, Ohio, part of Southern Ohio Medical Center.

Dr. Ling's NPI, 1871695700, was assigned on September 1, 2006. Dr. Ling graduated from UC San Diego School of Medicine in 1973. Dr. Ling holds Florida license ME77427.

Dr. Ling's primary practice is Southern Ohio Medical Center, at 1805 27th Street, Portsmouth, OH 45662 in Scioto County. The practice phone is (740) 356-8435.

Dr. Ling's primary practice is Southern Ohio Medical Center in Portsmouth, Ohio, part of Southern Ohio Medical Center. The medical group on file is Southern Ohio Medical Center. Dmand AI also links Dr. Ling to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ling practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Ling's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Ling is board certified in pediatrics by the American Board of Pediatrics. Dmand AI has Dr. Ling's licenses on file in 8 states: Florida, New York, California, Hawaii, New Hampshire, Ohio, Oregon and Oklahoma.

Dmand AI lists lung cancer radiation among the conditions Dr. Ling treats.

CMS data shows 397 Medicare services from Dr. Ling across 4 procedure codes in 2024, for 105 Medicare patients. Medicare paid $22,518 for them.

CMS counts 105 Medicare patients who saw Dr. Ling in 2024. The largest group is 65 to 74, with 49 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 1.43, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Ling's median patient age at 74, with 48% women.

In 2024, Dr. Ling wrote 47 Medicare Part D claims for 30 patients. 87% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $223 in total drug cost. In 2018, CMS named 16 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Ling for performance year 2024, reported through an alternative payment model (APM). Dr. Ling accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 7 papers to Dr. Ling, published from 2015 to 2021. The most frequent topics are Prostatic Neoplasms. Dr. Ling has published most often in Int J Radiat Oncol Biol Phys. Dr. Ling's most frequent co-authors are Aashish D. Bhatt, MD, Arnab Chakravarti, MD and Mack Roach, MD.

CMS Open Payments shows 33 general payments to Dr. Ling from 23 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Sumitomo Pharma America, Inc. paid the most, $250.

Dr. Ling graduated from UC San Diego School of Medicine in 1973.

Dr. Ling is in network with 13 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.